Teleconference of the R&D Blueprint GCM
January 20, 2020
Friday 13:00-13:55 GVA time

Pneumonia of unknown etiology in Wuhan China

Chairperson: Ana Maria Henao (Jeremy Farrar was unable to attend)
GCM members attendees – ; Evelyn Depoortere; Hillary Marston; Marie-Paule Kieny;
Yazdan Yayzanpanah; Thomas Palu; Anne Kinsey; Josie Golding;
WHO: A. Costa; X. Riveros; AM Henao; P Gsell, J. Diaz; Vasee Sathiyamoorthy, Marie-
Pierre Preziosi

Agenda items

1. WHO overview of emerging data on disease epidemiology
2. Share the latest progress on landscape Diagnostics Therapeutic candidates
   and Vaccine candidates
3. Partners update on their R&D activities for nCoV

Overview of the epidemiological situation and measures implemented to date

As of 20 January 2020, 282 confirmed cases of 2019-nCoV have been reported from
four countries including China (278 cases), Thailand (2 cases), Japan (1 case) and
the Republic of
Korea (1 case);
Cases in Thailand, Japan and Republic of Korea were exported from Wuhan City, China;
Among the 278 cases confirmed in China, 258 cases were reported from Hubei
Province, 14 from Guangdong Province, five from Beijing Municipality and one from
Shanghai Municipality;
Of the 278 confirmed cases, 51 cases are severely ill, 12 are in critical condition
Six deaths have been reported from Wuhan City.

WHO published preliminary guidance (e.g. early detection, clinical case
management) and has activated various networks of experts (e.g modelling, lab,
risk communications).

WHO response
• Developed the surveillance case definitions for human infection with 2019-nCoV
  and is updating it as per the new information becomes available;
• Developed interim guidance for laboratory diagnosis, clinical management,
infection prevention and control in health care settings, home care for mild
patients, risk communication and community engagement;
• Prepared disease commodity package for supplies necessary in identification and management of confirmed patients;
• Provided recommendations to reduce risk of transmission from animals to humans;
• Updated the travel advice for international travel in health in relation to the outbreak of pneumonia caused by a new coronavirus in China;
• Utilizing global expert networks and partnerships for laboratory, infection prevention and control, clinical management and mathematical modelling;
• Activation of R&D blueprint to accelerate diagnostics, vaccines, an therapeutics; a landscape analysis was produced in collaboration with BARDA, CEPI and London School; a master protocol to evaluate vx and tx efficacy is under discussion;
• WHO is working with our networks of researchers and other experts to coordinate global work on surveillance, epidemiology, modelling, diagnostics, clinical care and treatment, and other ways to identify, manage the disease and limit onward transmission. WHO has issued interim guidance for countries, updated to take into account the current situation.
• WHO is asking partners to share prepublication articles/manuscripts in advance in order to access to the latest information in real time
• Sequence sharing 11 Chinese, 5 was disclosed over the weekend and 1 Japanese sequence in GSIAD
• Virus sharing, countries are contacting WHO to facilitate and provide guidelines and principles Materials Transfer Agreements
• WHO is also working with the NRAs in at risk countries to facilitate the approvals and implementations for clinical trials.

Update from the partners

• INSEIRM and the French Research community, and GLOPID-R that have activities in China, Japan and Thailand to share all the information and also may have funds available support nCoV research. It would be useful if WHO can share the priority projects.
• NIH has a vaccine research programme at Vaccine Research Center and Rocky Mountain. In addition doing basic virology, preparing reagents animal models with Rocky Mountain Institute and ecological investigation. On diagnostic NIH is working in PCR and ELISA with CDC. On Therapeutics reviewing the data from Remdesivir and MERS.

Next steps and recommendations

• The landscape analysis are being completed and will be made public next week.
• Partners should share with WHO all the projects, activities and information on R&D and share new emerging evidence.